Benzinga | Sep 21, 2020 07:02AM EDT

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Which Will Include 1 Phase 3 Trial

Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021



Extensive patient safety database, previously obtained through Pfizer exclusive license, to support NDA filing

Extensive array of completed nonclinical studies sufficient to support NDA filing

Company to host conference call today at 8:00 AM Eastern